박사트 (VXRT) 주가

박사트(VXRT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.50 (+5.46%), 시가총액 $0.15B, PER (주가수익비율) 3.94, 52주 최저~최고 $0.30 ~ $0.80.

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervi

핵심 지표

• 현재가: $0.50 (+5.46%)
• 시가총액: $0.15B
• PER (주가수익비율): 3.94
• 52주 최저~최고: $0.30 ~ $0.80
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

박사트의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

박사트 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 1.75
• 순이익률: 0.15%
• 영업이익률: 0.13%

자주 묻는 질문